» Articles » PMID: 10093978

Visual Inspection with Acetic Acid for Cervical-cancer Screening: Test Qualities in a Primary-care Setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1999 Mar 27
PMID 10093978
Citations 53
Affiliations
Soon will be listed here.
Abstract

Background: Naked-eye visual inspection of the cervix with acetic-acid wash (VIA), or cervicoscopy, is an alternative to cytology in screening for cervical cancer in poorly resourced locations. We tested the sensitivity, specificity, and predictive value of VIA done by nurse-midwives in a less-developed country.

Methods: Women were screened by six trained nurse-midwives in a two-phase, cross-sectional study at 15 primary-care clinics in Zimbabwe. VIA and Pap smears were done concurrently, and their sensitivity and specificity compared. Colposcopy, with biopsy as indicated, was used as the reference test to allow a direct comparison of the test unaffected by verification bias.

Findings: 10934 women were screened. In phase II, 2148 (97.5%) of the 2203 participants for whom there was a screening result also had a reference test result. Also in phase II, VIA was more sensitive but less specific than cytology. Sensitivity (95% CI) was 76.7% (70.3-82.3) for VIA and 44.3% (37.3-51.4) for cytology. Specificity was 64.1% (61.9-66.2) for VIA and 90.6% (89.2-91.9) for cytology.

Interpretation: The high sensitivity of VIA shows that the test could be valuable in detection of precancerous lesions of the cervix. However, there are costs to the patient and system costs associated with high numbers of false-positive results, so attention should be given to improving the specificity of VIA.

Citing Articles

Comparison of acceptability & efficacy of thermal ablation (thermocoagulation) & cryotherapy in VIA positive cervical lesions: A pilot study.

Verma M, Sharma P, Singh U, Sachan R, Sankhwar P Indian J Med Res. 2023; 158(4):423-431.

PMID: 38006345 PMC: 10793829. DOI: 10.4103/ijmr.ijmr_1166_22.


Expression of p53 in toluidine blue positive oral squamous cell carcinoma lesions and expression of Ki67 in vinegar positive oral squamous cell carcinoma lesions.

Bhalang K, Danuthai K Front Oral Health. 2023; 4:1239961.

PMID: 37876530 PMC: 10593433. DOI: 10.3389/froh.2023.1239961.


Implementation and scale-up of a single-visit, screen-and-treat approach with thermal ablation for sustainable cervical cancer prevention services: a protocol for a stepped-wedge cluster randomized trial in Kenya.

Shin M, Oluoch L, Barnabas R, Baynes C, Fridah H, Heitner J Implement Sci. 2023; 18(1):26.

PMID: 37365575 PMC: 10294443. DOI: 10.1186/s13012-023-01282-3.


WHO should adjust its global strategy for cervical cancer prevention.

Suba E, Donnelly A, Duong D, Gonzalez Mena L, Neethling G, Thai N BMJ Glob Health. 2023; 8(6).

PMID: 37308263 PMC: 10277060. DOI: 10.1136/bmjgh-2023-012031.


A comparison of behavioural models explaining cervical cancer screening uptake.

Dsouza J, Van den Broucke S, Pattanshetty S, Dhoore W BMC Womens Health. 2022; 22(1):235.

PMID: 35710374 PMC: 9204900. DOI: 10.1186/s12905-022-01801-2.